PTH and chronic kidney disease: Post hoc analyses from pivotal clinical trials have shown that PTH analogs (teriparatide and abaloparatide) exhibit similar efficacy in increasing BMD and reducing fracture risk in patients with normal renal function and those with CKD stages G1–G3 who have stable biochemical parameters, including non-elevated endogenous PTH levels [17,62].